WEEK 0
HOW OFTEN ARE YOUR PATIENTS REMINDED OF THEIR DISEASE?
SKYRIZI IS NOT A DAILY PILL AND HAS NO LABELED FOOD RESTRICTIONS.
GIVE PATIENTS THE FREEDOM TO CHOOSE
ONLY
4
DOSES
A YEAR
AFTER INITIATION DOSES AT WEEKS 0 AND 41
ADULT ADMINISTRATION INSTRUCTIONS:
- SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI according to the Instructions for Use.1
- SKYRIZI is administered via a single 150 mg/mL subcutaneous injection every 12 weeks after initiation.1
- SKYRIZI may be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs) for patients with active PsA.1
- Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with SKYRIZI and complete all age-appropriate vaccinations as recommended by current immunization guidelines.
DOSING SCHEDULES
SKYRIZI IS THE ONLY 4-DOSE-A-YEAR SYSTEMIC IN PSORIASIS AND PSORIATIC ARTHRITIS THAT OFFERS A SINGLE-DOSE PEN1
DOSING SCHEDULES FOR SELECT SYSTEMICS FOR MODERATE TO SEVERE Ps1-9*
INJECTION
RECOMMENDED ADULT DOSING
TREATMENT INITIATION
SKYRIZI® (risankizumab-rzaa)
Ps dosing: 150 mg subcutaneous injection; every 12 weeks after initiation.
.
.
Initiation doses at Weeks 0 and 4
TREMFYA® (guselkumab)
Ps dosing: 100 mg subcutaneous injection; every 8 weeks after initiation.
.
.
Initiation doses at Weeks 0 and 4
BIMZELX® (bimekizumab-bkzx)
Ps dosing: 320 mg by subcutaneous injection at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter. For patients weighing 120 kg or more, consider a dosage of 320 mg every 4 weeks after Week 16.
.
.
.
.
.
Initiation doses at Weeks 0, 4, 8, 12, & 16
COSENTYX® (secukinumab)
Ps dosing: One 300 mg injection or two 150 mg injections; every 4 weeks after initiation; for some patients, 150 mg dose may be acceptable.
.
.
.
.
.
Once-weekly dosing for the first 5 doses
TALTZ® (ixekizumab)
Ps dosing: 80 mg subcutaneous injection; every 4 weeks after initiation.
.
.
.
.
.
.
.
160 mg (two 80 mg injections) at Week 0 followed by 80 mg every 2 weeks through Week 12
ORAL
SOTYKTU® (deucravacitinib)
Ps dosing: 6 mg oral tablet once daily
None
OTEZLA® (apremilast)
Ps dosing: 30 mg oral tablet twice daily following titration period.
OTEZLA XR™ (apremilast) 75 mg dosed once daily for maintenance after titration per label.
.
.
.
.
.
.
.
.
.
Day 1: 10 mg in AM; Day 2: 10 mg in AM and 10 mg in PM; Day 3: 10 mg in AM and 20 mg in PM; Day 4: 20 mg in AM and 20 mg in PM; Day 5: 20 mg in AM and 30 mg in PM
ICOTYDETM (icotrokinra)
Ps dosing: 200 mg oral tablet once daily.
None
YEARLY DOSING (AFTER INITIATION)
Based on doses required in each 48-week maintenance treatment period
SKYRIZI® (risankizumab-rzaa)
Every 12 Weeks
.
.
.
.
TREMFYA® (guselkumab)
Every 8 Weeks
.
.
.
.
.
.
BIMZELX® (bimekizumab-bkzx)
Every 8 Weeks
.
.
.
.
.
.
COSENTYX® (secukinumab)
Every 4 Weeks
.
.
.
.
.
.
.
.
.
.
.
.
TALTZ® (ixekizumab)
Every 4 Weeks
.
.
.
.
.
.
.
.
.
.
.
.
SOTYKTU® (deucravacitinib)
Once Daily
. X336
OTEZLA® (apremilast)
Twice Daily
. X 672
space-holder
Once Daily
. X 336
ICOTYDETM (icotrokinra)
Once Daily
. X 336
ILUMYA® (tildrakizumab-asmn) dosing: 100 mg subcutaneous injection; every 12 weeks after
initiation. Initiation doses at Weeks 0 and 4.
1 dot=1 dose
INDICATIONS
SKYRIZI® is indicated for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy and active psoriatic arthritis in adults and pediatric patients 6 years of age and older.
TREMFYA® is indicated for the treatment of adults and pediatric patients 6 years and older who also weigh at least 40 kg with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy and for the treatment of adult and pediatric patients 6 years and older who also weigh at least 40 kg with active psoriatic arthritis.
BIMZELX® is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and for the treatment of adults with active psoriatic arthritis.
COSENTYX® is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy and for the treatment of active psoriatic arthritis in patients 2 years of age and older.
TALTZ® is indicated for the treatment of patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy and for the treatment of adult patients with active psoriatic arthritis.
SOTYKTU® is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and for the treatment of active psoriatic arthritis in adults.
OTEZLA® is indicated for the treatment of pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and for the treatment of adult patients and pediatric patients 6 years of age and older and weighing at least 20 kg with active psoriatic arthritis.
OTEZLA XR™ is indicated for the treatment of pediatric patients 6 years of age and older and weighing at least 50 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and for the treatment of adult patients and pediatric patients 6 years of age and older and weighing at least 50 kg with active psoriatic arthritis.
ICOTYDE™ is indicated for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy.
ILUMYA® is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Products and their designs are trademarks of their respective owners.
This presentation is not intended to compare the efficacy or safety of the treatments shown. While these factors are important, there are additional considerations for selecting a treatment. Please refer to each product’s Prescribing Information for additional information.
SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Instruct patients to read the Instructions for Use before administration.1
Dosing schedules as of 3/18/2026.
*For select IL-17 inhibitors, select IL-23 inhibitors, a tyrosine kinase 2 inhibitor, a phosphodiesterase 4 (PDE4) inhibitor, and an IL-23 receptor antagonist.
DOSING SCHEDULES FOR SELECT SYSTEMICS FOR ACTIVE PsA1-6*
INJECTION
RECOMMENDED ADULT DOSING
TREATMENT INITIATION
SKYRIZI® (risankizumab-rzaa)
PsA dosing: 150 mg subcutaneous injection; every 12 weeks after initiation.
.
.
Initiation doses at Weeks 0 and 4
TREMFYA® (guselkumab)
PsA dosing: 100 mg subcutaneous injection; every 8 weeks after initiation.
.
.
Initiation doses at Weeks 0 and 4
BIMZELX® (bimekizumab-bkzx)
PsA recommended dosing: 160 mg by subcutaneous injection every 4 weeks.
For patients with PsA and coexistent moderate to severe Ps, the dosing and administration
recommendations for Ps should be used.
.
160 mg at Week 0
COSENTYX® (secukinumab)
PsA dosing: With a loading dosage: 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. Without a loading dosage: 150 mg every 4 weeks. If a patient continues to have active PsA, consider a dosage of 300 mg every 4 weeks.
For patients with PsA and coexistent moderate to severe Ps, the dosing and administration recommendations for Ps should be used.
IV dosing: With a loading dosage: 6 mg/kg at Week 0, followed by 1.75 mg/kg every 4 weeks thereafter (maintenance dosage). Without a loading dosage: 1.75 mg/kg every 4 weeks. Administer as an intravenous infusion over a period of 30 minutes.
.
.
.
.
.
Option to dose once-weekly for the first 5 doses or not initiate doses
TALTZ® (ixekizumab)
PsA recommended dosing: 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks.
For patients with PsA and coexistent moderate to severe Ps, the dosing regimen for adult Ps should be used.
.
160 mg (two 80 mg injections) at Week 0
ORAL
SOTYKTU® (deucravacitinib)
PsA dosing: 6 mg oral tablet once daily
None
OTEZLA® (apremilast)
PsA dosing: 30 mg oral tablet twice daily following titration period.
OTEZLA XR™ (apremilast) 75 mg dosed once daily for maintenance after titration per label.
.
.
.
.
.
.
.
.
.
Day 1: 10 mg in AM; Day 2: 10 mg in AM and 10 mg in PM; Day 3: 10 mg in AM and 20 mg in PM; Day 4: 20 mg in AM and 20 mg in PM; Day 5: 20 mg in AM and 30 mg in PM
YEARLY DOSING (AFTER INITIATION)
Based on doses required in each 48-week maintenance treatment period
SKYRIZI® (risankizumab-rzaa)
Every 12 Weeks
.
.
.
.
TREMFYA® (guselkumab)
Every 8 Weeks
.
.
.
.
.
.
BIMZELX® (bimekizumab-bkzx)
Every 4 Weeks
.
.
.
.
.
.
.
.
.
.
.
.
COSENTYX® (secukinumab)
Every 4 Weeks
.
.
.
.
.
.
.
.
.
.
.
.
TALTZ® (ixekizumab)
Every 4 Weeks
.
.
.
.
.
.
.
.
.
.
.
.
SOTYKTU® (deucravacitinib)
Once Daily
. X 336
OTEZLA® (apremilast)
Twice Daily
. X 672
space-holder
Once Daily
. X 336
1 dot=1 dose
INDICATIONS
SKYRIZI® is indicated for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy and active psoriatic arthritis in adults and pediatric patients 6 years of age and older.
TREMFYA® is indicated for the treatment of adults and pediatric patients 6 years and older who also weigh at least 40 kg with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy and for the treatment of adult and pediatric patients 6 years and older who also weigh at least 40 kg with active psoriatic arthritis.
BIMZELX® is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and for the treatment of adults with active psoriatic arthritis.
COSENTYX® is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy and for the treatment of active psoriatic arthritis in patients 2 years of age and older.
TALTZ® is indicated for the treatment of patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy and for the treatment of adult patients with active psoriatic arthritis.
SOTYKTU® is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and for the treatment of active psoriatic arthritis in adults.
OTEZLA® is indicated for the treatment of pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and for the treatment of adult patients and pediatric patients 6 years of age and older and weighing at least 20 kg with active psoriatic arthritis.
OTEZLA XR™ is indicated for the treatment of pediatric patients 6 years of age and older and weighing at least 50 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and for the treatment of adult patients and pediatric patients 6 years of age and older and weighing at least 50 kg with active psoriatic arthritis.
Products and their designs are trademarks of their respective owners.
This presentation is not intended to compare the efficacy or safety of the treatments shown. While these factors are important, there are additional considerations for selecting a treatment. Please refer to each product’s Prescribing Information for additional information.
SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Instruct patients to read the Instructions for Use before administration.1
Dosing schedules as of 3/18/2026.
*For select IL-17 inhibitors, IL-23 inhibitors, and a PDE4 inhibitor.
THE SAME DOSING FOR Ps AND PsA
ONLY 4 DOSES A YEAR AFTER INITIATION DOSES AT WEEKS 0 & 41
1 DOSAGE FOR ALL ADULT PATIENTS
REGARDLESS OF BASELINE WEIGHT, DISEASE SEVERITY, OR PRIOR TREATMENT1:
INITIATION
WEEK 4
MONTH 3
WEEK 16
MONTH 6
WEEK 28
MONTH 9
WEEK 40
MONTH 12
WEEK 52
RELIABLE 3-MONTH DOSING, ADMINISTERED BY A SINGLE 150 mg/mL SUBCUTANEOUS INJECTION1
THE MEAN HALF-LIFE IS APPROXIMATELY 28 DAYS FOR A TYPICAL PATIENT WITH Ps OR PsA.1
FLEXIBILITY TO CHOOSE BETWEEN1:
150 mg/mL single-dose pen
OR
150 mg/mL single-dose prefilled syringe
The SKYRIZI Pen was awarded an Ease of Use certification from the Arthritis Foundation's independent lab testing, which included psoriatic arthritis patients.10
ADULT ADMINISTRATION INSTRUCTIONS: SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI according to the Instructions for Use.
SKYRIZI may be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs) for patients with active PsA.1
DOSING DESIGNED SPECIFICALLY FOR PEDIATRIC PATIENTS
REGARDLESS OF DISEASE SEVERITY OR PRIOR TREATMENT1:
ONLY IL-23i APPROVED FOR Ps OR PsA IN PATIENTS AGES 6+ WEIGHING LESS THAN 40 kg
Less than 40 kg: 55 mg/injection
single-dose prefilled syringe
Greater than or equal to 40 kg: 150 mg/injection
single-dose prefilled syringe or pen
INITIATION
WEEK 0
WEEK 4
MONTH 3
WEEK 16
MONTH 6
WEEK 28
MONTH 9
WEEK 40
MONTH 12
WEEK 52
RELIABLE 3-MONTH DOSING, ADMINISTERED BY A SINGLE SUBCUTANEOUS INJECTION1
PEDIATRIC ADMINISTRATION INSTRUCTIONS: SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Caregivers may administer SKYRIZI to pediatric patients after training in subcutaneous injection technique. Provide proper training to caregivers on the subcutaneous injection technique of SKYRIZI according to the Instructions for Use.
For pediatric patients 10 years of age and older, it is recommended that SKYRIZI be administered by or under the supervision of an adult. For pediatric patients 6 to less than 10 years of age, SKYRIZI should be administered by an adult.
SKYRIZI may be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs) for patients with active PsA.1
Prescribing SKYRIZI
to your patients?
See what formulary coverage for
SKYRIZI looks like.
INJECTION SUPPORT VIDEOS
FOR ADULT PATIENTS TAKING EITHER 150 mg/mL SKYRIZI PEN OR 150 mg/mL PREFILLED SYRINGE
